Y-mabs presents sada platform preclinical data and trial in progress posters at the 2024 american society hematology (ash) annual meeting

New york, dec. 07, 2024 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of cd38-sada in non-hodgkin lymphoma (nhl) preclinical data and trial in progress posters at the 66th american society of hematology (ash) annual meeting & exposition being held on december 7 –10, 2024, in san diego, california.
YMAB Ratings Summary
YMAB Quant Ranking